Researchers sought to determine whether CAR-T therapy could improve HR-QoL scores for patients with relapsed or refractory multiple myeloma.

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

Multiple Myeloma (MM), a chronic and currently incurable hematologic malignancy, remains one of the most dynamic and competitive therapeutic landscapes in oncology. Originating from abnormal plasma ...

Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

For people with newly diagnosed multiple myeloma (NDMM), who are unsuitable for a procedure where damaged blood cells are replaced with healthy ones (stem-cell transplant), treatment is usually a ...

Lynozyfic’s global sales are projected to reach $707 million by 2031.